Comparison of the effects of 2-deoxyglucose and immobilization on secretion and synthesis rate of catecholamines in the adrenal gland: a microdialysis study in conscious rats.
Using microdialysis, extracellular 3,4-dihydroxyphenylalanine (DOPA), noradrenaline (NA) and adrenaline (AD) concentrations in the adrenal gland were monitored in conscious rats during and after 60 min of immobilization (IMM) as well as after injection of 500 mg kg(-1) 2-deoxyglucose (2-DG). IMM produced a rapid and transient increase in secretion of AD (20-fold), NA (13-fold) and DOPA (3.6-fold). This was accompanied by an increase in blood pressure (+18 mmHG) and heart rate (+146 b.p.m.). Repeated exposure to IMM (daily 60 min, for 5 days) had no influence on either catecholamine secretion of haemodynamic profiles, indicating the lack of habituation to stressful conditions. Unlike IMM, the stress of 2-DG-induced central neuroglucopenia stimulated the release of AD without affecting NA secretion. AD levels peaked (5.1-fold increase) 40-60 min after 2-DG injection and then slowly declined. 2-DG induced no changes in blood pressure but reduced the heart rate (-48 b.p.m.). In separate experiments, steady-state dialysate DOPA levels, reached during continuous infusion of decarboxylase inhibitor NSD 1015 into adrenal gland tissue through the dialysis probe, served as an index of adrenomedullary tyrosine hydroxylase (TH) activity. IMM evoked a marked response in TH activity (DOPA formation increased 2.7-fold), which remained elevated 60 min after the cessation of stress when AD and NA secretion had already fallen to baseline. After 2-DG, despite significant hormonal response, adrenal TH activity was unchanged. These results give clear evidence that IMM and 2-DG-induced neuroglucopenia may be considered as two different types of stressful stimuli.
Kuzmin
A I
AI
Institute of Experimental Cardiology, National Cardiology Research Centre, Moscow, Russia.
Pogorelov
V M
VM
Zaretsky
D V
DV
Medvedev
O S
OS
Chazov
E I
EI
D000311:Adrenal Glands / Q000378:metabolism*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002395:Catecholamines / Q000096:biosynthesis* / Q000378:metabolism; D003847:Deoxyglucose / Q000494:pharmacology*; D004295:Dihydroxyphenylalanine / Q000096:biosynthesis / Q000378:metabolism; D004837:Epinephrine / Q000096:biosynthesis / Q000378:metabolism; D006339:Heart Rate / Q000187:drug effects; D007103:Immobilization / Q000502:physiology*; D008297:Male; D017551:Microdialysis; D009638:Norepinephrine / Q000096:biosynthesis / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013312:Stress, Physiological / Q000378:metabolism*; D013997:Time Factors
D002395:Catecholamines; D004295:Dihydroxyphenylalanine; D003847:Deoxyglucose; D009638:Norepinephrine; D004837:Epinephrine